145 related articles for article (PubMed ID: 38374206)
1. Delineating functional and molecular impact of ex vivo sample handling in precision medicine.
Struyf N; Österroos A; Vesterlund M; Arnroth C; James T; Sunandar S; Mermelekas G; Bohlin A; Hamberg Levedahl K; Bengtzén S; Jafari R; Orre LM; Lehtiö J; Lehmann S; Östling P; Kallioniemi O; Seashore-Ludlow B; Erkers T
NPJ Precis Oncol; 2024 Feb; 8(1):38. PubMed ID: 38374206
[TBL] [Abstract][Full Text] [Related]
2. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
3. The influence of delay in mononuclear cell isolation on acute myeloid leukemia phosphorylation profiles.
van Alphen C; Cucchi DGJ; Cloos J; Schelfhorst T; Henneman AA; Piersma SR; Pham TV; Knol JC; Jimenez CR; Janssen JJWM
J Proteomics; 2021 Apr; 238():104134. PubMed ID: 33561558
[TBL] [Abstract][Full Text] [Related]
4. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Kohler S; Bacher U; Pabst T
Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
[TBL] [Abstract][Full Text] [Related]
5. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.
Dehmel U; Zaborski M; Meierhoff G; Rosnet O; Birnbaum D; Ludwig WD; Quentmeier H; Drexler HG
Leukemia; 1996 Feb; 10(2):261-70. PubMed ID: 8637235
[TBL] [Abstract][Full Text] [Related]
8. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
9. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Brauchle B; Goldstein RL; Karbowski CM; Henn A; Li CM; Bücklein VL; Krupka C; Boyle MC; Koppikar P; Haubner S; Wahl J; Dahlhoff C; Raum T; Rardin MJ; Sastri C; Rock DA; von Bergwelt-Baildon M; Frank B; Metzeler KH; Case R; Friedrich M; Balazs M; Spiekermann K; Coxon A; Subklewe M; Arvedson T
Mol Cancer Ther; 2020 Sep; 19(9):1875-1888. PubMed ID: 32518207
[TBL] [Abstract][Full Text] [Related]
11. French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study.
Garnham A; Bruon F; Berthon C; Lebon D; Parimi M; Polya R; Makhloufi KM; Dramard-Goasdoue MH
Oncol Ther; 2023 Sep; 11(3):375-389. PubMed ID: 37578642
[TBL] [Abstract][Full Text] [Related]
12. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
Rosen DB; Minden MD; Kornblau SM; Cohen A; Gayko U; Putta S; Woronicz J; Evensen E; Fantl WJ; Cesano A
PLoS One; 2010 Oct; 5(10):e13543. PubMed ID: 21048955
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive and unbiased multiparameter high-throughput screening by compaRe finds effective and subtle drug responses in AML models.
Chalabi Hajkarim M; Karjalainen E; Osipovitch M; Dimopoulos K; Gordon SL; Ambri F; Rasmussen KD; Grønbæk K; Helin K; Wennerberg K; Won KJ
Elife; 2022 Feb; 11():. PubMed ID: 35166670
[TBL] [Abstract][Full Text] [Related]
15. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia.
Auewarakul CU; Lauhakirti D; Promsuwicha O; Munkhetvit C
Ann Hematol; 2006 Feb; 85(2):108-12. PubMed ID: 16320053
[TBL] [Abstract][Full Text] [Related]
16. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract][Full Text] [Related]
17. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
[TBL] [Abstract][Full Text] [Related]
18. High-Throughput Proteomic Analysis of Fresh-Frozen Biopsy Tissue Samples Using Pressure Cycling Technology Coupled with SWATH Mass Spectrometry.
Zhu Y; Guo T
Methods Mol Biol; 2018; 1788():279-287. PubMed ID: 29071490
[TBL] [Abstract][Full Text] [Related]
19. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
20. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
